Acute promyelocytic leukemia and constitutional trisomy 21

Cancer Genetics and Cytogenetics
Carla KurkjianMohamed A Kharfan-Dabaja

Abstract

The incidence of acute myelogenous leukemia (AML) in patients with constitutional trisomy 21 is estimated to be 1 in 300; it is usually seen before age four. Clinical and epidemiological data confirm the improved life expectancy of patients with Down syndrome and their increased susceptibility to the development of leukemia, among other cancers. The most frequent subtype of AML associated with Down syndrome is acute megakaryoblastic leukemia (FAB: M7). The description of acute promyelocytic leukemia (APL) in adult patients with Down syndrome is exceedingly rare. Herein, we describe the unusual presentation, treatment, results, and clinical course of an adult patient with APL and constitutional trisomy 21 and provide a brief review of the literature.

References

Dec 1, 1991·Cancer Genetics and Cytogenetics·P OsellaA Milunsky
Jan 1, 1994·Cancer Genetics and Cytogenetics·I MiuraA B Miura
Jul 15, 1993·The New England Journal of Medicine·R P WarrellL Degos
May 30, 2001·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·M L ChauffailleJ Kerbauy
Jan 22, 2002·Cancer Genetics and Cytogenetics·Derrick W SpellWilliam S Velasquez
Dec 31, 2002·Cancer Genetics and Cytogenetics·Alfonso ZaccariaGiovanni Martinelli
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S de BottonP Fenaux
Feb 3, 2005·Journal of the National Cancer Institute·Yubin GeJeffrey W Taub

❮ Previous
Next ❯

Citations

Nov 27, 2007·Journal of Medical Case Reports·Deepali JainPrerna Arora
Jul 31, 2007·Critical Reviews in Oncology/hematology·Kathrin T DoepfnerAlexandre Arcaro
Apr 8, 2011·British Journal of Haematology·Mayuko TsudaKohichiro Tsuji
Aug 12, 2016·Current Hematologic Malignancy Reports·Neha BhatnagarIrene Roberts
Jul 29, 2009·Journal of Pediatric Hematology/oncology·Indranil GhoshVasantha Thavraj
Feb 27, 2019·Journal of Pediatric Hematology/oncology·Yusuke TsumuraDaisuke Tomizawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.